comprehensive -WSS

comprehensive

author：entertainment 2025-09-14 14:42:22 - browse：94721

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Novo Nordisk to buy Cardior, building up pipeline of heart drugs

explore

Wikipedia

WSS

Pharma patents targeted by Biden in move to slash drug prices

Pfizer plans to depart BIO

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Americans' trust in science, scientist continues decline: Report

Steward Health Care expansion into Malta flopped

Erich Jarvis studies song birds to learn about human stuttering

Wikipedia

comprehensive

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Chinese researcher claims birth of first gene

Dobbs anniversary: the lost opportunity of abortion as health care

This gene therapy has record $4.25 million price. It's saved children.

In Memoriam: Notable people who died in 2023

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Medical leaders decry Supreme Court decision on affirmative action

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

After affirmative action ruling, medical educators look to 'holistic review'

Pfizer, Moderna say biotech, pharma drug development is a sprint

entertainment

Adam's Take: Intra

What causes an itch? Researchers may have solved the mystery

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Bring on the sabbaticals for nurses

Medical devices makers are asking for forgiveness, not permission

Yancopoulos of Regeneron works to expand Dupixent success

hotspot

explore

Wikipedia

entertainment